Telomir Pharmaceuticals, Inc. (TELO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Telomir Pharmaceuticals, Inc., an emerging growth company incorporated in Florida, on September 4, 2025. The report covers events occurring on August 28, 2025, specifically regarding a completed equity offering.
Key Financial Metrics
The filing details a capital raise event rather than standard operating financials. Key metrics from the transaction include:
- Shares Sold: 1,550,000 shares of common stock.
- Average Price: $1.87 per share.
- Gross Proceeds: Approximately $2.9 million (prior to fees and expenses).
- Trading Venue: The Nasdaq Stock Market LLC.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in outstanding common stock and cash assets resulting from the block sale. The shares were sold at a premium to the prior day's closing price. The transaction was executed through the company's at-the-market equity offering facility via the StockBlock platform, facilitated by Rodman & Renshaw.
Outlook, Risks, and Unusual Items
The offering did not include any warrants. As this is a current report focused on a specific transaction, the filing does not contain updated forward-looking guidance, management commentary on operational outlook, or a discussion of general risks and contingencies beyond the execution of the sale.
Investor Verification Checklist
- Verify the net proceeds after deducting fees and expenses from the $2.9 million gross amount.
- Confirm the updated total number of outstanding shares following the issuance of 1,550,000 new shares.
- Review the company's most recent 10-Q or 10-K for current cash balance and burn rate to assess the impact of the new capital.
- Check for any subsequent filings regarding the use of proceeds or changes in the at-the-market offering facility.